Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study

• Published in: Blood Vol. 128; no. 22; p. 114
• Main Authors: Garcia-Manero, Guillermo, Odenike, Olatoyosi, Amrein, Philip C., Steensma, David P., DeZern, Amy E., Michaelis, Laura C., Faderl, Stefan, Kantarjian, Hagop M., Lowder, James N., Taverna, Pietro, Oganesian, Aram, Zhang, Xiaoping, Azab, Mohammad, Savona, Michael R.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 02.12.2016

▪ Introduction: Patients with International Prognostic Scoring System (IPSS) intermediate 1 and 2 (Int) and high risk (HR) MDS benefit from therapy with hypomethylating agents (HMAs) decitabine (DAC) and azacitidine (AZA). Treatment requires 5 or 7 daily parenteral doses every month while the patien...